Revenue for the full 2008 increased 44.3% to a record $46.8 million compared with $32.4 million in 2007. The increase in revenues for 2008 is primarily attributable to a general increase in the price of plasma-based products which was partially offset by the sales volume decrease except for human immunoglobulin, and the foreign exchange translation, which accounted for 12.5% of the increase. All of the Company's approved products, except for human rabies immunoglobulin, recorded price increases ranging from 29.7% to 227.7%. During 2008, the SFDA implemented the new 90-day quarantine period on plasma raw material, effective July 1, 2008. This new measure further tightened the availability of raw material for production, and has adversely impacted the already short supply of plasma-based products. The price increase of plasma-based products between 2007 and 2008 was primarily attributable to the PRC government's stringent control on the quality standard of the plasma-based production industry, which resulted in a shortage in the supply of finished products. China Biologic was able to adjust its production plan to take advantage of the limited market supply of plasma resources and realize higher profit margins by developing a portfolio of high margin products and increasing the yield per unit volume of plasma.
Sales breakdown of the Company's major plasma-based products includes the
approved human albumin products, which accounted for 57.8% of sales in 2008,
as compared to 63.4% in 2007. Sales volume of human albumin produ
|SOURCE China Biologic Products, Inc.|
Copyright©2009 PR Newswire.
All rights reserved